Rhythm Pharmaceuticals (RYTM) Operating Leases (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Operating Leases data on file, last reported at $3.2 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $3.2 million, down 17.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (down 17.61% YoY), and the FY2025 annual result was $3.3 million, down 15.13% from the prior year.
• Operating Leases eased to $3.2 million in Q1 2026 per RYTM's latest filing, from $3.3 million in the prior quarter.
• Over five years, Operating Leases peaked at $4.0 million in Q3 2024 and troughed at $284000.0 in Q1 2024.
• A 5-year average of $2.3 million and a median of $2.4 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases plunged 73.61% in 2024, then soared 1251.76% in 2025.
• A 5-year view of Operating Leases shows it stood at $1.3 million in 2022, then plunged by 61.11% to $490000.0 in 2023, then soared by 703.67% to $3.9 million in 2024, then slipped by 15.13% to $3.3 million in 2025, then dropped by 5.36% to $3.2 million in 2026.
• Business Quant data shows RYTM's Operating Leases at $3.2 million in Q1 2026, $3.3 million in Q4 2025, and $3.5 million in Q3 2025.